CN115932265A - 预测cd19抗体治疗在患者中的治疗益处的方法 - Google Patents

预测cd19抗体治疗在患者中的治疗益处的方法 Download PDF

Info

Publication number
CN115932265A
CN115932265A CN202211271570.5A CN202211271570A CN115932265A CN 115932265 A CN115932265 A CN 115932265A CN 202211271570 A CN202211271570 A CN 202211271570A CN 115932265 A CN115932265 A CN 115932265A
Authority
CN
China
Prior art keywords
cells
peripheral
baseline
lymphoma
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211271570.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·恩德尔
M·温德尔里奇
R·博克斯哈默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG filed Critical Morphosys AG
Publication of CN115932265A publication Critical patent/CN115932265A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202211271570.5A 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法 Pending CN115932265A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16171885.3 2016-05-30
EP16171885 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
CN201780033793.9A CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780033793.9A Division CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Publications (1)

Publication Number Publication Date
CN115932265A true CN115932265A (zh) 2023-04-07

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211271570.5A Pending CN115932265A (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法
CN201780033793.9A Active CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780033793.9A Active CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Country Status (27)

Country Link
US (2) US20190195879A1 (enExample)
EP (2) EP3916392B1 (enExample)
JP (2) JP7066639B2 (enExample)
KR (1) KR102416144B1 (enExample)
CN (2) CN115932265A (enExample)
AU (1) AU2017272608B2 (enExample)
BR (1) BR112018074603A2 (enExample)
CY (1) CY1124768T1 (enExample)
DK (2) DK3916392T3 (enExample)
EA (1) EA201892542A1 (enExample)
ES (2) ES2981046T3 (enExample)
FI (1) FI3916392T3 (enExample)
HR (2) HRP20210938T1 (enExample)
HU (2) HUE067450T2 (enExample)
IL (1) IL263103B2 (enExample)
LT (2) LT3916392T (enExample)
MA (2) MA45124B1 (enExample)
MD (2) MD3916392T2 (enExample)
MX (2) MX388502B (enExample)
PL (2) PL3916392T3 (enExample)
PT (2) PT3916392T (enExample)
RS (2) RS62155B1 (enExample)
SG (2) SG11201810159TA (enExample)
SI (2) SI3916392T1 (enExample)
SM (2) SMT202100291T1 (enExample)
WO (1) WO2017207574A1 (enExample)
ZA (2) ZA201808647B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017032679A1 (en) 2015-08-21 2017-03-02 Morphosys Ag Combinations and uses thereof
AU2017348624B2 (en) 2016-10-28 2024-09-26 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
JP2022532519A (ja) 2019-05-03 2022-07-15 モルフォシス・アーゲー 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
PH12022551021A1 (en) * 2019-10-31 2023-03-06 Morphosys Ag Sequential anti-cd19 therapy
IL292181A (en) * 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
IL303384A (en) * 2020-12-04 2023-08-01 Morphosys Ag Anti-CD19 combination therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060233791A1 (en) * 2005-02-15 2006-10-19 Duke University Anti-CD19 antibodies and uses in oncology
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
US20140328842A1 (en) * 2011-12-12 2014-11-06 Pikamab, Inc. Predicting Responsiveness to Antibody Maintenance Therapy
US20150239974A1 (en) * 2014-02-25 2015-08-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
WO2015195498A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1041221A1 (zh) * 1998-08-11 2002-07-05 Idec药物公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008032217A2 (fr) * 2006-09-13 2008-03-20 Glycode Methode d'investigation de la reponse a un traitement par un anticorps monoclonal
ES2659517T3 (es) 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
CA2817842A1 (en) * 2010-11-15 2012-05-24 Medimmune, Llc Combination therapy for b cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR20140064873A (ko) * 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
JP6805137B2 (ja) * 2014-07-11 2020-12-23 アンセルム（アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 血液学的癌を診断するための方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060233791A1 (en) * 2005-02-15 2006-10-19 Duke University Anti-CD19 antibodies and uses in oncology
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
US20140328842A1 (en) * 2011-12-12 2014-11-06 Pikamab, Inc. Predicting Responsiveness to Antibody Maintenance Therapy
US20150239974A1 (en) * 2014-02-25 2015-08-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
WO2015195498A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)

Also Published As

Publication number Publication date
KR102416144B1 (ko) 2022-07-04
PL3465214T3 (pl) 2021-12-20
CN109313194A (zh) 2019-02-05
SMT202100291T1 (it) 2021-07-12
MD3916392T2 (ro) 2024-10-31
ES2878156T3 (es) 2021-11-18
MA45124B1 (fr) 2021-05-31
KR20190013980A (ko) 2019-02-11
PT3916392T (pt) 2024-06-04
DK3465214T3 (da) 2021-05-31
EP3916392B1 (en) 2024-05-01
CY1124768T1 (el) 2022-11-25
ZA201808647B (en) 2021-05-26
SG10201911958SA (en) 2020-02-27
PT3465214T (pt) 2021-06-30
HUE067450T2 (hu) 2024-10-28
MX388502B (es) 2025-03-20
WO2017207574A1 (en) 2017-12-07
MD3465214T2 (ro) 2021-09-30
ZA202100296B (en) 2025-05-28
EP3916392A1 (en) 2021-12-01
MA45124A (fr) 2017-12-07
US20190195879A1 (en) 2019-06-27
JP2019519770A (ja) 2019-07-11
LT3916392T (lt) 2024-08-26
IL263103A (en) 2018-12-31
IL263103B2 (en) 2023-10-01
MX2018014702A (es) 2019-10-02
SG11201810159TA (en) 2018-12-28
CA3025823A1 (en) 2017-12-07
JP7066639B2 (ja) 2022-05-13
EA201892542A1 (ru) 2019-06-28
BR112018074603A2 (pt) 2019-03-19
HRP20240670T1 (hr) 2024-09-27
SI3916392T1 (sl) 2024-10-30
LT3465214T (lt) 2021-10-11
AU2017272608B2 (en) 2023-08-10
NZ748468A (en) 2025-05-30
IL263103B1 (en) 2023-06-01
RS62155B1 (sr) 2021-08-31
HUE054860T2 (hu) 2021-10-28
DK3916392T3 (da) 2024-05-21
JP7511806B2 (ja) 2024-07-08
EP3465214A1 (en) 2019-04-10
HRP20210938T1 (hr) 2021-09-03
MA57021B1 (fr) 2024-05-31
EP3465214B1 (en) 2021-04-28
AU2017272608A1 (en) 2018-12-06
US20220283166A1 (en) 2022-09-08
SMT202400204T1 (it) 2024-09-16
MX2021014963A (es) 2022-02-24
SI3465214T1 (sl) 2021-12-31
RS65540B1 (sr) 2024-06-28
ES2981046T3 (es) 2024-10-07
FI3916392T3 (fi) 2024-06-03
CN109313194B (zh) 2022-11-04
PL3916392T3 (pl) 2024-09-23
JP2022119764A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
US12297282B2 (en) Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)
JP7511806B2 (ja) 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
KR20220091576A (ko) 혈액암의 항-cd47 및 항-cd20 기반 치료
US20220242952A1 (en) Anti-cd19 therapy in patients having a limited number of nk cells
HK40065007A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40065007B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
EA040320B1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
NZ788788A (en) Methods for predicting therapeutic benefit of anti-CD19 therapy in patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250316

Address after: Delaware, USA

Applicant after: INCYTE Corp.

Country or region after: U.S.A.

Address before: Praneger, Germany

Applicant before: MORPHOSYS AG

Country or region before: Germany